EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The adiponectin‐derived peptide ALY688 protects against the development of metabolic dysfunction‐associated steatohepatitis

Zhe Huang iD, Hye Kyoung Sung iD, Xingqun Yan iD, Shiyu He iD, Leigang Jin iD, Qin Wang iD, Xuerui Wu iD, Henry H Hsu iD, Angelica Pignalosa iD, Kathryn Crawford iD, Gary Sweeney iD, Aimin Xu iD

Clinical and Translational Science · 2024-06 · 17 (6)

DOI: 10.1111/cts.13760 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Science, online erschienen am 07.06.2024. Verfasst von Zhe Huang und 11 weiteren Autor:innen. Beteiligte Einrichtung: The State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Hong Kong, China. Hauptthemen laut MEDLINE: Adiponectin, Disease Models, Animal, Hepatocytes, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction‐associated steatohepatitis (MASH) is the severe form of non‐alcoholic fatty liver disease which has a high potential to progress to cirrhosis and hepatocellular carcinoma, yet adequate effective therapies are lacking. Hypoadiponectinemia is causally involved in the pathogenesis of MASH. This study investigated the pharmacological effects of adiponectin replacement therapy with the adiponectin‐derived peptide ALY688 (ALY688‐SR) in a mouse model of MASH. Human induced pluripotent stem (iPS) cell‐derived hepatocytes were used to test cytotoxicity and signaling of unmodified ALY688 in vitro. High‐fat diet with low methionine and no added choline (CDAHF) was used to induce MASH and test the effects of ALY688‐SR in vivo. Histological MASH activity score (NAS) and fibrosis score were determined to assess the effect of ALY688‐SR. Transcriptional characterization of mice through RNA sequencing was performed to indicate potential molecular mechanisms involved. In cultured hepatocytes, ALY688 efficiently induced adiponectin‐like signaling, including the AMP‐activated protein kinase and p38 mitogen‐activated protein kinase pathways, and did not elicit cytotoxicity. Administration of ALY688‐SR in mice did not influence body weight but significantly ameliorated CDAHF‐induced hepatic steatosis, inflammation, and fibrosis, therefore effectively preventing the development and progression of MASH. Mechanistically, ALY688‐SR treatment markedly induced hepatic expression of genes involved in fatty acid oxidation, whereas it significantly suppressed the expression of pro‐inflammatory and pro‐fibrotic genes as demonstrated by transcriptomic analysis. ALY688‐SR may represent an effective approach in MASH treatment. Its mode of action involves inhibition of hepatic steatosis, inflammation, and fibrosis, possibly via canonical adiponectin‐mediated signaling.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdiponectinDisease Models, AnimalHepatocytesNon-alcoholic Fatty Liver DiseasePeptide FragmentsAnimalsHumansMiceDiet, High-FatFatty LiverLiverMetabolic DiseasesMetabolism, Inborn ErrorsMice, Inbred C57BLSignal Transduction

Substanzen

AdiponectinPeptide Fragments

Autor:innen und Institutionen

  • The State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Hong Kong, China.
  • Department of Medicine, The University of Hong Kong, Hong Kong, China.
  • Department of Genetics and Developmental Science, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China.
  • Department of Biology, York University, Toronto, Ontario, Canada.
  • Allysta Pharmaceuticals, Bellevue, Washington, USA.
  • Department of Pharmacology and Pharmacy, The University of Hong Kong, Hong Kong, China.

ORCID-Profile: Zhe Huang, Hye Kyoung Sung, Xingqun Yan, Shiyu He, Leigang Jin, Qin Wang, Xuerui Wu, Henry H Hsu, Angelica Pignalosa, Kathryn Crawford, Gary Sweeney, Aimin Xu

Zitieren

APA

Huang, Z., Sung, H. K., Yan, X., He, S., Jin, L., Wang, Q., Wu, X., Hsu, H. H., Pignalosa, A., Crawford, K., Sweeney, G., & Xu, A. (2024). The adiponectin‐derived peptide ALY688 protects against the development of metabolic dysfunction‐associated steatohepatitis. Clinical and Translational Science, 17(6). https://doi.org/10.1111/cts.13760

Vancouver

Huang Z, Sung HK, Yan X, He S, Jin L, Wang Q, et al. The adiponectin‐derived peptide ALY688 protects against the development of metabolic dysfunction‐associated steatohepatitis. Clinical and Translational Science. 2024;17(6). doi:10.1111/cts.13760

BibTeX
@article{Huang2024,
  author = {Huang, Zhe and Sung, Hye Kyoung and Yan, Xingqun and He, Shiyu and Jin, Leigang and Wang, Qin and Wu, Xuerui and Hsu, Henry H and Pignalosa, Angelica and Crawford, Kathryn and Sweeney, Gary and Xu, Aimin},
  title = {The adiponectin‐derived peptide ALY688 protects against the development of metabolic dysfunction‐associated steatohepatitis},
  journal = {Clinical and Translational Science},
  year = {2024},
  volume = {17},
  number = {6},
  doi = {10.1111/cts.13760}
}
Kostenlos starten →